Tested across a range of colorectal, lung, skin, and pancreatic cancer cell lines in vitro, BI-3406 displays KRAS-mutant cancer specific activity, capable of inducing apoptosis through MAPK inhibition. Here, KRAS is linked to familial pancreatic carcinoma.